logo
Kymera Therapeutics_Logo
Kymera is developing novel heterobifunctional degraders that target degradation of both IRAK4 and IMiD substrates, Ikaros and Aiolos, with a single small molecule. KT-413 is designed to address both the IL-1R/TLR and the Type 1 IFN pathways synergistically to broaden activity against MYD88-mutant B cell malignancies.

Kymera Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Business Update

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today reported business highlights and financial results for the third quarter ended September 30, 2022

By Kymera Therapeutics, Inc.
Published - Nov 03, 2022, 07:08 AM ET
Last Updated - Mar 19, 2024, 10:19 AM EDT

Completed patient cohort portion (Part C) of the IRAK4 degrader KT-474 Phase 1 trial

Patient data from KT-474 and clinical oncology pipeline to be presented in December, 2022

Raised $150 million through private placement equity financing; September 30, 2022, cash balance of $596 million

Company to hold quarterly results call at 8:30 a.m. EST (800-715-9871)

Article Source
Quick Links
Categories
Our Offices
  • 10kInfo, Inc.
    13555 SE 36th St
    Bellevue, WA 98006
  • 10kInfo Data Solutions, Pvt Ltd.
    Claywork Create
    11 km, Arakere Bannerghatta Rd, Omkar Nagar, Arekere,
    Bengaluru, Karnataka 560076
4.2 12182024